Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-alpha 2a:

R M Bukowski1, S Murthy, J Sergi

  • 1Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Ohio 44195-5236.

Journal of Biological Response Modifiers
|December 1, 1990
PubMed